Stock版 - Is it true or not about BCRX? |
|---|
|
|
|
|
|
|
b******7
发帖数: 733 | 1 http://seekingalpha.com/article/182425-biocryst-peramivir-approval-opens-japanese-market
BioCryst Pharmaceuticals (BCRX) announced that their Jpanaese partner,
Shionogi & Co., has been granted approval for peramivir in Japan, triggering
the third $7 million clinical development milestone payment from Shionogi
to BioCryst. BioCryst will receive an additional $95 million as commercial
milestones are achieved. In addition, BioCryst receives a 10% to 20% royalty
on Shionogi's sales, and will capture | b******7
发帖数: 733 | 2 Based on his caculation, the Japan market itself will push the stock price
to 20-30$. Why the price still is only $ 8?
triggering
royalty
in
peramivir
【在 b******7 的大作中提到】
: http://seekingalpha.com/article/182425-biocryst-peramivir-approval-opens-japanese-market
: BioCryst Pharmaceuticals (BCRX) announced that their Jpanaese partner,
: Shionogi & Co., has been granted approval for peramivir in Japan, triggering
: the third $7 million clinical development milestone payment from Shionogi
: to BioCryst. BioCryst will receive an additional $95 million as commercial
: milestones are achieved. In addition, BioCryst receives a 10% to 20% royalty
: on Shionogi's sales, and will capture
|
|
|
|
|
|
|
|
